Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

Szentpéteri, Anita; Lőrincz, Hajnalka; Somodi, Sándor; Varga, V.; Paragh, György; Serés, I.; Harangi, Mariann

doi:10.1186/s12944-018-0691-y

Cited by 9 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in accordance with a study by Zhang et al who suggested that obestatin levels were significantly reduced in obese rodents [18]. In the study of Szentpéteri, they concluded that a reduction of obestatin could contribute to the development of the metabolic syndrome and impaired rate of lipoprotein metabolism in obese patients [19].…”

Section: Discussionsupporting

confidence: 91%

Plasma levels of obestatin and ghrelin and obestatin/ghrelin ratio in obese patients

Sfar¹,

Jemaa²,

Kallel³

et al. 2022

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Background: Obestatin and ghrelin are two gastric hormones that have a potential role in dietary intake regulation. Obestatin/ghrelin ratio has been proposed as activity markers in obesity. The study aimed to evaluate ghrelin, obestatin and the ghrelin/obestatin ratio in obese compared to control subjects and to determine their relationship with anthropometric and metabolic parameters. Methods: Fasting obestatin and ghrelin levels were measured using enzyme-linked immunosorbent assay ELISA in 28 obese and 24 healthy subjects. The fasting ghrelin/obestatin ratio was calculated. Anthropometric and metabolic parameters were also assessed. Results: Obese patients had significantly lower obestatin and ghrelin blood levels compared with controls. The Ghrelin/Obestatin ratio was significantly lower in obese group 0.813±0.0417 ng/ml than in the control group 0.896±0.049 ng/ml, (p<0.001). In obese patients, obestatin and ghrelin were significantly and negatively correlated with BMI and positively correlated with HDL-C. Conclusion: Circulating preprandial ghrelin to obestatin ratio is decreased obese subjects. We suggest that low preprandial ghrelin to obestatin ratio may be involved in the etiology and pathophysiology of obesity.

show abstract

Section: Discussionsupporting

confidence: 91%

Plasma levels of obestatin and ghrelin and obestatin/ghrelin ratio in obese patients

Sfar¹,

Jemaa²,

Kallel³

et al. 2022

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…Serum and EDTA plasma samples were kept frozen at −70°C for enzyme-linked immunosorbent assay (ELISA) measurements and for subsequent lipoprotein subfraction analysis. In our work, we followed the methods of Szentpéteri et al [ 26 ].…”

Section: Methodsmentioning

confidence: 99%

“…LDL subfractions were also detected using Lipoprint System (Quantimetrix Corp., CA, USA) [ 26 ] according to the instructions of the manufacturer. 25 μ l sera were added to polyacrylamide gel tubes along with 200 μ l Sudan Black containing a loading gel solution.…”

Section: Methodsmentioning

confidence: 99%

Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects

Somodi

Serés

Lőrincz

et al. 2018

International Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Background The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals. Subjects and Methods We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry. Results The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients. Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction. Conclusion The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.

show abstract

“…Szentpéteri et al described lower circulating obestatin in NDO patients compared to lean, healthy ones [ 145 ]. Negative correlations were found between BMI, glucose, insulin and HbA1c, VLDL subfraction and obestatin, while HDL-C, ApoAI and mean LDL size correlated positively with obestatin highlighting the possible favorable role of obestatin in morbid obesity.…”

Section: Role Of Novel Hepatokines and Gastrointestinal Hormones In N...mentioning

confidence: 99%

Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity

et al. 2023

Self Cite

View full text Add to dashboard Cite

Obesity is characterized by an excessive accumulation of fat leading to a plethora of medical complications, including coronary artery disease, hypertension, type 2 diabetes mellitus or impaired glucose tolerance and dyslipidemia. Formerly, several physiological roles of organokines, including adipokines, hepatokines, myokines and gut hormones have been described in obesity, especially in the regulation of glucose and lipid metabolism, insulin sensitivity, oxidative stress, and low-grade inflammation. The canonical effect of these biologically active peptides and proteins may serve as an intermediate regulatory level that connects the central nervous system and the endocrine, autocrine, and paracrine actions of organs responsible for metabolic and inflammatory processes. Better understanding of the function of this delicately tuned network may provide an explanation for the wide range of obesity phenotypes with remarkable inter-individual differences regarding comorbidities and therapeutic responses. The aim of this review is to demonstrate the role of organokines in the lipid and glucose metabolism focusing on the obese non-diabetic subgroup. We also discuss the latest findings about sarcopenic obesity, which has recently become one of the most relevant metabolic disturbances in the aging population.

show abstract

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

Cited by 9 publications

References 32 publications

Plasma levels of obestatin and ghrelin and obestatin/ghrelin ratio in obese patients

Plasma levels of obestatin and ghrelin and obestatin/ghrelin ratio in obese patients

Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects

Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity

Contact Info

Product

Resources

About